Literature DB >> 22310184

Connective tissue disease: Trial of SLE therapies in real-world settings.

Manuel Ramos-Casals, Munther A Khamashta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22310184     DOI： 10.1038/nrrheum.2012.4

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

Review 1.  Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.

Authors:  M Aringer; H Burkhardt; G R Burmester; R Fischer-Betz; M Fleck; W Graninger; F Hiepe; A M Jacobi; I Kötter; H J Lakomek; H M Lorenz; B Manger; G Schett; R E Schmidt; M Schneider; H Schulze-Koops; J S Smolen; C Specker; T Stoll; A Strangfeld; H P Tony; P M Villiger; R Voll; T Witte; T Dörner
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

2.  [B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice].

Authors:  Manuel Ramos-Casals; Cándido Díaz-Lagares; Munther A Khamashta
Journal:  Med Clin (Barc)       Date:  2010-06-02       Impact factor: 1.725

Review 3.  Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting.

Authors: 
Journal:  Arthritis Rheum       Date:  2004-11

4.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

5.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

6.  The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

Authors:  Bridget Griffiths; Paul Emery; Vicky Ryan; David Isenberg; Mohammed Akil; Robert Thompson; Peter Maddison; Ian D Griffiths; Alice Lorenzi; Sarah Miles; Deva Situnayake; Lee Suan Teh; Mike Plant; Christina Hallengren; Ola Nived; Gunnar Sturfelt; Kuntal Chakravarty; Tim Tait; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2010-01-16       Impact factor: 7.580

7.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

8.  Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Authors:  Ellen M Ginzler; David Wofsy; David Isenberg; Caroline Gordon; Laura Lisk; Mary-Anne Dooley
Journal:  Arthritis Rheum       Date:  2010-01

9.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.